ERBB2 and breast cancer: A previous study reported that on a 2D 400 Pa matrix, the incorporation of EdU, which is an indicator of cell proliferation, was approximately 50%, whereas in a 3D 400 Pa Matrigel, the EdU incorporation was approximately 20% following lapatinib treatment in HER2+ breast cancer cell line [70].